СARDIOTONIC STEROIDS NEUTRALIZATION AS A THERAPEUTIC APPROACH IN PREECLAMPSIA

Preeclampsia (PE) is a serious complication of late pregnancy.

Objective. To study and to explore the possibilities of neutralization of cardiotonic steroids, to define the possible mechanisms of recovery activity Na/K-ATPase in pregnant women with PE for the prevention of vasospasm.

Design and methods. The study was carried out in two stages. Firstly, two groups of pregnant women were included. Control group consisted of 6 women with normal pregnancy with gestational age 37–40–3/7 weeks. The main group consisted of 7 women with PE with a comparable gestational age (mean systolic blood pressure 157 ±5 mm Hg, diastolic blood pressure 94 ±2 mm Hg, and urinary protein excretion 2,12 ± 0,46 g/day). At the second stage, 12 patients with PE (aged 29 ± 1 year, gestation 37,9 ± 0,6 weeks, blood pressure 159 ± 5 / 99 ±3 mm Hg) formed the main group. The control group included 11 healthy pregnant women comparable by gestational age. Venous blood samples were taken. Marinobufagenin level was determined by fluoroimmunoassay, spectrophotometry was used to assess the activity of erythrocyte Na/K-ATPase in the presence and absence of monoclonal antibody, DigiFab, magnesium sulfate.

Results. The level of marinobufagenin in pregnant women with preeclampsia was almost 2,5-fold higher than in control group (1,056 vs. 0,421 nM). The activity of erythrocyte Na/K-ATPase in pregnant women with preeclampsia was 1,47 ± 0,1716 and 2,65 ± 0,16 mcmol Fn/mL/h (p < 0,01), respectively. When incubated with monoclonal antibodies erythrocyte Na/K–ATPase activity was 2,41 mcmol Fn/mL/h. When incubated with DigiFab there was a 3,5-fold increase in PE marinobufagenin plasma levels (1,38 ± 0,40 vs. 0,38 ± 0,10 nmol/L, p < 0,01) and a reduction of the erythrocyte Na/K–ATPase activity compared to control group (1,16 ± 0,11 vs. 2,80 ± 0,2 mkmol Fn/ml/h, p < 0,01). Ex vivo, 1 ug/ml DigiFab restores the activity of Na/K–ATPase (1,72 ± 0,13 mkmol Fn/ml/h, p < 0,01) and3 mM magnesium sulfate amplifies DigiFab effect (2,3 ± 0,2 mkmol Fn/mL/h, p < 0,01).

1. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97(4):533–538.

2. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785–799.

3. Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology and novel therapeutic targets. Pharmacol Rev. 2009;61(1):9–38.

4. Graves SW. The possible role of digitalis-like factors in pregnancy-induced hypertension. Hypertension. 1987;10 (5 Pt 2):184–186.

5. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens. 1999;17(8):1179–1187.

6. Fedorova OV, Shapiro JI, Bagrov AY. Endogenous cardiotonic steroids and hypertension. Biochem Biophys Acta — Mol Bas Dis. 2010;1802(12):1230–1236.

7. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, Anderson DE. Plasma marinobufagenin-like and ouabainlike immunoreactivity during acute saline volume expansion in anesthetized dogs. Cardiovasc Res. 1996;31(2):296–305.

8. Fedorova OV, Simbirtsev AS, Kolodkin NI, Kotov AY, Agalakova NI, Kashkin VA et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsiainduced Na/K–ATPase inhibition in lowers blood pressure in NaClsensitive hypertension. J Hypertens 2008;26(12):2414–2425.

9. Adair CD, Buckalew VM, Kipikasa J, Torres C, Stallings SP, Briery CM. Repeated dosing of digoxin-fragmented antibody in preterm eclampsia. J Perinatol. 2009;29(2):163–165.

10. Fedorova OV, Lakatta EG, Bagrov AY. Differential effects of acute NaCl loading on endogenous ouabain-like and marinobufagenin-like ligands of the sodium pump in Dahl hypertensive rats. Circulation. 2000;102:3009–3014.

11. Fedorova OV, Tapilskaya NI, Bzhelyansky AM, Frolova EV, Nikitina ER, Reznik VA et al. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae. J Hypertension. 2010;28(2):361–366.

12. Яковлева В. В., Солодовникова Н. Г., Фролова Е. В., Адэр Д. С., Федорова О. В., Зазерская И. Е. и др. Digifab и иммунонейтрализация кардиотонических стероидов при преэклампсии (краткое сообщение). Артериальная гипертензия. 2011;17(4):391–396. [Yakovleva VV, Solodovnikova NG, Frolova EV, Adair CD, Fedorova OV, Zazerskaya IE et al. DIGIFAB and immunoneutralization cardiotonic steroids in preeclampsia. Arterial’naya Gipertenziya = Arterial Hypertension. 2011;17 (4):391–396. In Russian].

13. Fedorova OV, Kolodkin NI, Agalakova NI, Namikas AR, Bzhelyansky A, St-Louis J et al. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens. 2005;23(4):835–842.

14. Zazerskaya IE, Ishkaraeva VV, Frolova EV, Solodovnikova NG, Grigorova YN, David Adair C et al. Magnesium sulfate potentiates effect of Digifab on marinobufagenin-induced Na/K– ATPase inhibition. Am J Hypertens. 2013;26 (11):1269–1272.